omblastys
y-mabs therapeutics a/s - iodine (131i) omburtamab - neuroblastom - terapeutiske radioaktive lægemidler - treatment of neuroblastoma.
moniyot-131 capsule t 37-7400 mb kapsler, hårde
monrol europe s.r.l. - natriumiodid (131-i) - kapsler, hårde - 37-7400 mb
lipiodol ultra fluid 480 mg/ml injektionsvæske, opløsning
guerbet - joderet olie - injektionsvæske, opløsning - 480 mg/ml
mammit-io 3 mg/ml pattebadevand, opløsning
ferdinand eimermacher gmbh & co. - iod - pattebadevand, opløsning - 3 mg/ml - kvæg
lipiodol ultra fluid 480 mg/ml injektionsvæske, opløsning
orifarm a/s - joderet olie - injektionsvæske, opløsning - 480 mg/ml
lipiodol ultra fluid 480 mg/ml injektionsvæske, opløsning
2care4 aps - joderet olie - injektionsvæske, opløsning - 480 mg/ml
tekcis radionuklidgenerator
cis bio international oris ind. - natriummolybdat (99m-mo) - radionuklidgenerator
visipaque 270 mg iod/ml injektionsvæske, opløsning
ge healthcare as - iodixanol - injektionsvæske, opløsning - 270 mg iod/ml
thyrogen
sanofi b.v. - thyrotropin alfa - thyroid neoplasms - hypofyseforlaps lap hormoner og analoger, hypofyse og hypothalamus hormoner og analoger - thyrogen is indicated for use with serum thyroglobulin (tg) testing with or without radioiodine imaging for the detection of thyroid remnants and well-differentiated thyroid cancer in post thyroidectomy patients maintained on hormone suppression therapy (thst). low risk patients with well-differentiated thyroid carcinoma who have undetectable serum tg levels on thst and no rh (recombinant human) tsh-stimulated increase of tg levels may be followed-up by assaying rh tsh-stimulated tg levels. thyrogen is indicated for pre-therapeutic stimulation in combination with a range of 30 mci (1. 1 gbq) to 100 mci (3. 7 gbq) radioiodine for ablation of thyroid tissue remnants in patients who have undergone a near-total or total thyroidectomy for well-differentiated thyroid cancer and who do not have evidence of distant metastatic thyroid cancer (see section 4.